Regencell Bioscience Holdings Ltd (RGC) stock
RGCNasdaqMedicinal Chemicals & Botanical Products
$4.69+0.14 (+3.08%)
Close on Nov 18, 2026Market cap $2.33BP/E –Yield –
Regencell Bioscience operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
For fiscal 2026 it was -$11.72M. The highest annual figure on record is -$390.99K in fiscal 2019.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Jun 30, 2026 | -$11.72M | – |
| FY2025 | Jun 30, 2025 | -$3.77M | – |
| FY2024 | Jun 30, 2024 | -$4.74M | – |
| FY2023 | Jun 30, 2023 | -$6.27M | – |
| FY2022 | Jun 30, 2022 | -$7.62M | – |
| FY2021 | Jun 30, 2021 | -$1.38M | – |
| FY2020 | Jun 30, 2020 | -$812.37K | – |
| FY2019 | Jun 30, 2019 | -$390.99K | – |
See a number that looks wrong?